Search results for "ldl"

showing 10 items of 664 documents

Editor's Note: Relates to: ‘Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to p…

2020

Aims The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD). Methods and results Of the theoretical estimated prevalence of 1/500 for heterozygous FH, <1% are diagnosed in most countries. Recently, direct screening in a Northern European general population diagnosed approximately 1/200 with heterozygous FH. All reported studies document failure to achieve recommended LDL cholesterol targets in a large proportion of individuals with FH, and up to 13-fold increased risk of CHD. Based on prevalen…

AdultMaleHeterozygoteConsensusCost-Benefit AnalysisCoronary DiseaseRisk AssessmentHyperlipoproteinemia Type IIHumansAcademicSubjects/MED00200ChildAnticholesteremic AgentsLow-density lipoproteinHomozygoteCholesterol LDLMiddle AgedCardiovascular diseaseAtherosclerosisCorrigendaPedigreeCoronary heart diseaseCholesterolEarly DiagnosisTreatment OutcomeCurrent OpinionChild PreschoolMutationFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsDelivery of Health CareForecastingEuropean Heart Journal
researchProduct

Influence of genetic variation at the apo A-I gene locus on lipid levels and response to diet in familial hypercholesterolemia

1998

We have examined the apo AI - 75 (G/A) and apo AI + 83(MspI +/-) polymorphisms at the APOA1 gene locus for associations with plasma lipid levels and response to an NCEP-I diet in 69 (44 women, 25 men) heterozygotes for familial hypercholesterolemia (FH). Subjects were studied at baseline (after consuming for one month a diet with 35%, fat, 10% saturated, and 300 mg/day cholesterol) and after 3 months of an NCEP-I diet. No gender-related differences for any of the lipid variables examined were found and the data were analyzed for men and women combined. For the apo AI - 75 (G/A) polymorphism, there were 51 G/G and 18 G/A subjects. At baseline, G/A subjects showed significantly lower total ch…

AdultMaleHeterozygotemedicine.medical_specialtyGenotypeApolipoprotein BCholesterol VLDLLocus (genetics)Familial hypercholesterolemiaHyperlipoproteinemia Type IIchemistry.chemical_compoundInternal medicineGenetic variationAPOA1 GenemedicineHumansAlleleAllelesGeneticsPolymorphism GeneticApolipoprotein A-IbiologyCholesterolCholesterol HDLGenetic VariationHeterozygote advantageCholesterol LDLmedicine.diseaseLipidsDietEndocrinologychemistrybiology.proteinFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

Evaluation of clinical diagnosis criteria of familial ligand defective apoB 100 and lipoprotein phenotype comparison between LDL receptor gene mutati…

2007

Familial hypercholesterolemia (FH) and familial defective apoB 100 (FDB) are characterized by increased plasma low-density lipoprotein cholesterol (LDLc) levels and risk of coronary heart disease (CHD). FDB is clinically indistinguishable from FH. The aims of this study were to evaluate clinical diagnosis criteria for FDB and to compare the lipoprotein phenotype between carriers of LDL receptor (LDLR) gene mutations that affect the ligand-binding domain and subjects with the R3500Q mutation in apoB gene. We studied 213 subjects (113 probands) with FH and 19 heterozygous FDB subjects. Genetic diagnosis was determined by following a protocol based on Southern blot and polymerase chain reactio…

AdultMaleHeterozygotemedicine.medical_specialtyGenotypeApolipoprotein BPopulationMutation MissenseCoronary DiseaseFamilial hypercholesterolemiaGene mutationBiologyWhite PeopleHyperlipoproteinemia Type IIchemistry.chemical_compoundPhysiology (medical)Internal medicinemedicineHumansMissense mutationeducationPolymorphism Single-Stranded Conformationaleducation.field_of_studyBinding SitesCholesterolGenetic Carrier ScreeningBiochemistry (medical)Public Health Environmental and Occupational HealthCholesterol LDLGeneral MedicineMiddle Agedmedicine.diseaseFounder EffectProtein Structure TertiaryEuropePhenotypeEndocrinologyReceptors LDLchemistryApolipoprotein B-100LDL receptorbiology.proteinFemalelipids (amino acids peptides and proteins)LipoproteinTranslational Research
researchProduct

Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients

2017

Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol with co-dominant transmission and high risk of cardiovascular disease (CVD), although with high variability among subjects. Currently, CVD stratification tools for heterozygous FH (HeFH) are not available. A definition of severe HeFH has been recently proposed by the International Atherosclerosis Society (IAS), but it has not been validated. Our study aims to see clinical characteristics and prevalence of CVD in subjects defined as severe HeFH by IAS criteria. Probable or definite HeFH introduced in the Dyslipidemia Registry of Spanish Arteriosclerosis Society were analyzed by the IAS crite…

AdultMaleHeterozygotemedicine.medical_specialtyMultivariate analysisFamilial hypercholesterolemia030204 cardiovascular system & hematologyRisk AssessmentSeverity of Illness IndexHyperlipoproteinemia Type IITendons03 medical and health sciences0302 clinical medicineMuscular DiseasesInternal medicineSeverity of illnessPrevalenceXanthomatosismedicineHumans030212 general & internal medicineUnivariate analysisbusiness.industryCholesterol LDLOdds ratioArteriosclerosisMiddle Agedmedicine.diseaseLogistic ModelsEndocrinologyCardiovascular DiseasesMultivariate AnalysisCardiologyFemaleCardiology and Cardiovascular MedicinebusinessRisk assessmentDyslipidemiaThe American Journal of Cardiology
researchProduct

Dietary polyunsaturated fatty acids may increase plasma LDL-cholesterol and plasma cholesterol concentrations in carriers of an ABCG1 gene single nuc…

2011

Abstract Background ABCG1 mediates cellular cholesterol transport, but there is very little known about the influence of ABCG1 polymorphisms on human plasma lipoprotein cholesterol concentrations or on the interactions of these polymorphisms with diet. Objective Our objective was to investigate whether interactions between PUFA intake and ABCG1 polymorphisms modulate associations with plasma total cholesterol (TC), LDL- and HDL-cholesterol in two Spanish populations. Methods We grounded our investigation on two general population-based studies: the Hortega study (population A) and the Pizarra study (population B). Participants included 1178 individuals (50.0% women, age range 21–85 years) a…

AdultMaleHeterozygotemedicine.medical_specialtyPopulationSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideYoung Adultchemistry.chemical_compoundGene FrequencySurveys and QuestionnairesInternal medicineGenotypemedicineHumansGene–environment interactionAlleleeducationAllele frequencyATP Binding Cassette Transporter Subfamily G Member 1AgedAged 80 and overchemistry.chemical_classificationGeneticseducation.field_of_studyChi-Square DistributionCholesterolHomozygoteCholesterol LDLMiddle AgedDietUp-RegulationCholesterolPhenotypeEndocrinologychemistrySpainFatty Acids UnsaturatedATP-Binding Cassette TransportersFemaleGene-Environment Interactionlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinePolyunsaturated fatty acidAtherosclerosis
researchProduct

Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern…

2005

We tested the hypothesis that gemfibrozil has a differential effect on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclass distributions and postprandial lipemia that is different in subjects classified as having LDL subclass pattern A or LDL pattern B who do not have a classic lipid disorder. Forty-three normolipemic subjects were randomized to gemfibrozil (1,200 mg/day) or placebo for 12 weeks. Lipids and lipoproteins were determined by enzymatic methods. The mass concentrations of lipoproteins in plasma were determined by analytic ultracentrifugation and included the S(f) intervals: 20 to 400 (very LDL), 12 to 20 (intermediate-density lipoprotein), 0 to 12 (LDL), an…

AdultMaleHyperlipoproteinemiasmedicine.medical_specialtySmall dense ldlLipid disorderApolipoprotein BLipoproteins VLDLPlacebochemistry.chemical_compoundDouble-Blind MethodInternal medicinemedicineHumansGemfibrozilTriglyceridesAgedHypolipidemic Agentsbiologybusiness.industryMiddle AgedPostprandial PeriodLipoproteins LDLTreatment OutcomeEndocrinologyPostprandialchemistryLow-density lipoproteinbiology.proteinFemalelipids (amino acids peptides and proteins)GemfibrozilLipoproteins HDLCardiology and Cardiovascular MedicinebusinessGemfibrozil small low-density lipoprotein pattern B pattern ABiomarkersLipoproteinmedicine.drug
researchProduct

Analysis of LDL and HDL size and number by nuclear magnetic resonance in a healthy working population: The LipoLab Study

2020

Background and aim Atherosclerosis is the underlying process in cardiovascular disease (CVD), the first cause of death in developed countries. We aimed to identify people with no known CVD and normal values of LDL-C and HDL-C, but with alterations in the number and size of lipoprotein particles (as measured by nuclear magnetic resonance [NMR]) and to analyse their sociodemographic, clinical and biochemical characteristics. Methods Cross-sectional study in occupational risks prevention centre in Castellon (Spain) in 2017 and 2018, in consecutively recruited adults (18-65 years) with no known CVD. Sociodemographic, clinical and biochemical variables were collected. Lipid profiles were analyse…

AdultMaleMagnetic Resonance SpectroscopyAdolescentLipoproteinsNormal valuesfamily practice030204 cardiovascular system & hematologyLogistic regressionLipoprotein particleYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNuclear magnetic resonancecardiovascular diseaseHumansWorking populationMedicine030212 general & internal medicineAgedCause of deathLDL particlesbusiness.industryCholesterolCholesterol HDLGeneral MedicineMiddle AgedNMRCross-Sectional StudiesBlood pressurechemistrySpainHDL particlesFemalelipids (amino acids peptides and proteins)businessLipoproteinInternational Journal of Clinical Practice
researchProduct

The effect of olive oil polyphenols on antibodies against oxidized LDL. A randomized clinical trial

2010

summary Background & aim: Oxidized LDL (oxLDL) is a highly immunogenic particle that plays a key role in the development of atherosclerosis. Some data suggest a protective role of OxLDL autoantibodies (OLAB) in atherosclerosis. Our aim was to assess the effect of olive oil polyphenols on the immunogenicity of oxLDL to autoantibody generation. Methods: In a crossover, controlled trial, 200 healthy men were randomly assigned to 3-week sequences of 25 mL/day of 3 olive oils with high (366 mg/kg), medium (164 mg/kg), and low (2.7 mg/kg) phenolic content. Results: Plasma OLAB concentration was inversely associated with oxLDL (p < 0.001). Olive oil phenolic content increased OLAB generation, with…

AdultMaleOxidized low density lipoproteinCritical Care and Intensive Care MedicineOxidative damageYoung AdultTandem Mass SpectrometryHumansPlant OilsMedicineFood scienceOlive OilChromatography High Pressure LiquidAutoantibodiesCross-Over StudiesNutrition and Dieteticsbiologybusiness.industryAutoantibodyPolyphenolsMiddle AgedLipoproteins LDLOxidative StressBiochemistryPolyphenolLinear Modelsbiology.proteinlipids (amino acids peptides and proteins)Lipid PeroxidationAntibodybusinessOxidized ldlOlive oilClinical Nutrition
researchProduct

Associations of Birth Weight and Postnatal Weight Gain With Cardiometabolic Risk Parameters at 5 Years of Age

2014

The present prospective study assessed the impact of birth weight (BW) and postnatal weight gain on blood pressure and metabolic profile during the first 5 years of life. One hundred thirty-nine newborns (63 women) born at term after uncomplicated pregnancies and in the absence of perinatal illness were included. Subjects were divided according to size at birth in small, appropriate, and large for gestational age. After the initial evaluation on the second day of life, infants were followed up at 6 months and 2 and 5 years. Anthropometric parameters and blood pressure were measured at each visit and metabolic assessment was performed at 5 years of age. Among the BW groups, mothers did not d…

AdultMalePediatricsmedicine.medical_specialtyBirth weightPhysiologyHemodynamicsBlood PressureGestational AgeWeight GainBody Mass Indexchemistry.chemical_compoundRisk FactorsInternal MedicinemedicineBirth WeightHumansInsulinMetabolomicsProspective StudiesProspective cohort studyTriglyceridesPregnancybusiness.industryInfant NewbornInfantGestational ageCholesterol LDLmedicine.diseaseUric AcidBlood pressurechemistryChild PreschoolLinear ModelsUric acidFemalemedicine.symptombusinessWeight gainFollow-Up StudiesHypertension
researchProduct

Latvian registry of familial hypercholesterolemia: The first report of three-year results.

2018

Abstract Background and aims Familial hypercholesterolemia (FH) was rarely diagnosed in Latvia before 2015, when the Latvian Registry of FH (LRFH) was established. Here, we report the first experience of the LRFH over three years (2015–2017). Methods The LRFH is an ongoing nationwide, dynamic, long-term prospective cohort. The diagnosis of FH was assessed using the Dutch Lipid Clinic Network (DLCN) criteria. Cascade screening of first-degree relatives using age- and sex-specific percentiles of low-density lipoprotein cholesterol (LDL-C) was performed in relatives of patients with definite and probable FH. Results Among the 416 individuals included in the LRFH, 181 patients were diagnosed wi…

AdultMalePediatricsmedicine.medical_specialtyStatinHeredityTime Factorsmedicine.drug_classDown-RegulationCascade screeningFamilial hypercholesterolemia030204 cardiovascular system & hematologyRisk AssessmentHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumansGenetic Predisposition to Disease030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyLipid clinicLipoprotein cholesterolAgedbusiness.industryAnticholesteremic AgentsMean ageCholesterol LDLMiddle Agedmedicine.diseaseLatviaCoronary heart diseasePedigreePhenotypeTreatment OutcomeCardiovascular DiseasesDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersAtherosclerosis
researchProduct